Predict your next investment

Venture Capital
palosanto.vc

See what CB Insights has to offer

Investments

9

Portfolio Exits

1

Funds

1

About Palo Santo

Palo Santo provides venture capital investments as a psychedelic therapeutics investment fund.

Palo Santo Headquarter Location

Chicago, Illinois,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Palo Santo News

How Investors Choose the Next Best Psychedelic Company

Mar 31, 2022

The venture capital team at Palo Santo has one of the most impressive portfolios in the psychedelics industry—25 of the top psychedelics and mental health companies in the world. And it’s the team itself that has attracted those companies, with many having impressive investment expertise and others with serious scientific depth in biotech, such as Dr. John Greden . Greden is the professor of Psychiatry and Clinical Neurosciences at the University of Michigan, founder and executive director of the University of Michigan Depression Center, founding chair of the National Network of Depressions Centers, and research professor at the Michigan Neurosciences institute. The company also has a commercialization strategy, including patent protection around the molecule, and does actual science. “Where we do most of our diligence is around the actual science,” Tim Schlidt, cofounder and partner of Palo Santo, told Psychedealia. “Since you are pre-revenue in this space for a very long period of time, you don’t really see product-market fits like you do in other industries, where you’re seeing a certain revenue ramp or kind of an exponential growth curve. And you are not getting a sense of this resonating with the market. So what we really look for is predictive pharmacology models, whether it’s animals, in vivo, in vitro, and then, of course, later on in humans.” When it comes to mental health disorders, it’s usually depression, bipolar disorder, or PTSD. “Those are such wide patient populations, where the underlying root causes are probably very different,” Schlidt said. “What gives me hope is that this (mental health) is a wide and deep field of inquiry. We’re all going to have jobs the next two or three decades as we start to really understand and explore the mind more.” Palo Santo launched its first psychedelic investment fund on July 15, 2021 , shortly after the company was formed in 2020, after raising a more-than-expected $35 million. Schlidt said that they made the assessment that, if psychedelics treatment is just for depression or PTSD, and that’s pretty much it in terms of the range of indications these can address, they may not be a very investable universe. But then they saw what was really happening with psychedelics. “On psychedelics, I think there’s a lot of optimism that it does, indeed, go beyond depression and PTSD, whether it’s more indications within the mental health realm, for example, eating disorders and things like that, or even beyond whether it’s neuropathic pain,” he said. “There’s been a lot of discussion of fibromyalgia, cluster headaches, and migraines.” One of their portfolio companies, Eleusis , is working on the anti-inflammatory benefits of psychedelics. “So I’m in full agreement with the view that there is a wide range of potential indications beyond just the core mental health verticals,” he said. Recent news about the psychedelics market shows some companies quitting, others consolidating, and most of the other top companies trading on various stock markets struggling to begin a slow recovery from low points earlier this year are not really an issue, he said. “I would say don’t look at the stock market too much,” he said. “There’s a lot of retail interest in the space. And it’s an interesting space where what really drives value inflection points are about hitting milestones and hitting preclinical or clinical milestones. I think the market is looking for real catalysts. But biotech is slow.” Schlidt likes the movements of academia into the psychedelics space recently, with such developments as Johns Hopkins Center for Psychedelic and Consciousness Research , and NYU’s Center for Psychedelic Medicine making a bigger commitment to psychedelics studies. “It gives a lot of validation to the space without a doubt, to see major universities pursuing this,” he said. “But with that said, I will say I think the academic studies, the way they tend to run trials, are a little less rigorous than we tend to see in the biotech realm. So it’s a nice first step, but there is a sort of passing the baton that biotech is going to have to perform here from the world of academia to add more rigor, more kind of FDA grade, clinical trial paths around, researching a lot of these compounds.” So what does the future of the industry portend? “I think you are definitely going to see a bit of separation of the wheat from the chaff in the space,” Schlidt said. “And I think that bolsters the case that you really need to be a diligent, selective (portfolio) manager in the space and that the just kind of spray-and-pray bet in psychedelics isn’t going to pay off. You really have to do your diligence on these companies. “I think we’re going to start seeing this space really get traction and really get buy-in from a wide swath of investors and other stakeholders. So that’s certainly our bets.” The Palo Santo fund will mainly invest in companies that are in the early stages of their fundraising, but could eventually begin investing in the late-stage rounds as well, co-founder Daniel Goldberg was quoted as saying in a press release . He added that the fund would also look to invest in companies whose operations go beyond just the production of psilocybin and focus on the development of new compounds based on it or its delivery methods. Post Views:

Palo Santo Investments

9 Investments

Palo Santo has made 9 investments. Their latest investment was in Fluence as part of their Seed VC on February 2, 2022.

CBI Logo

Palo Santo Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/28/2022

Seed VC

Fluence

$3M

Yes

2

2/25/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

10/29/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

9/27/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

9/21/2021

Seed VC

Subscribe to see more

Subscribe to see more

10

Date

2/28/2022

2/25/2022

10/29/2021

9/27/2021

9/21/2021

Round

Seed VC

Series A

Seed VC

Series A

Seed VC

Company

Fluence

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$3M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

10

10

Palo Santo Portfolio Exits

1 Portfolio Exit

Palo Santo has 1 portfolio exit. Their latest portfolio exit was ATAI Life Sciences on June 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/18/2021

IPO

$99M

17

Date

6/18/2021

Exit

IPO

Companies

Valuation

$99M

Acquirer

Sources

17

Palo Santo Fund History

1 Fund History

Palo Santo has 1 fund, including Palo Santo I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Palo Santo I

2

Closing Date

Fund

Palo Santo I

Fund Type

Status

Amount

Sources

2

Palo Santo Team

2 Team Members

Palo Santo has 2 team members, including current Founding Partner, Tim Schlidt.

Name

Work History

Title

Status

Daniel Goldberg

Founder

Current

Tim Schlidt

Founding Partner

Current

Name

Daniel Goldberg

Tim Schlidt

Work History

Title

Founder

Founding Partner

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.